MAIA Biotechnology Files 8-K

Ticker: MAIA · Form: 8-K · Filed: Jun 4, 2024 · CIK: 1878313

Maia Biotechnology, INC. 8-K Filing Summary
FieldDetail
CompanyMaia Biotechnology, INC. (MAIA)
Form Type8-K
Filed DateJun 4, 2024
Risk Levellow
Pages4
Reading Time5 min
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, regulatory

TL;DR

MAIA Bio filed an 8-K on June 4th, check it for updates.

AI Summary

MAIA Biotechnology, Inc. filed an 8-K on June 4, 2024, reporting on various events. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company is incorporated in Delaware and its principal executive offices are located in Chicago, IL.

Why It Matters

This 8-K filing provides updates and disclosures from MAIA Biotechnology, Inc. to the SEC, which are important for investors to understand the company's current status and any material events.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report and does not contain specific news that would immediately impact risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for MAIA Biotechnology, Inc.?

This 8-K filing serves to report on various events including Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits, as of June 4, 2024.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on June 4, 2024.

In which state is MAIA Biotechnology, Inc. incorporated?

MAIA Biotechnology, Inc. is incorporated in Delaware.

What is the address of MAIA Biotechnology, Inc.'s principal executive offices?

The principal executive offices of MAIA Biotechnology, Inc. are located at 444 West Lake Street, Suite 1700, Chicago, IL 60606.

What is the telephone number for MAIA Biotechnology, Inc.?

The telephone number for MAIA Biotechnology, Inc. is (312) 416-8592.

Filing Stats: 1,131 words · 5 min read · ~4 pages · Grade level 14.1 · Accepted 2024-06-04 16:06:02

Filing Documents

Forward-looking Statements

Forward-looking Statements The Company cautions that all statements, other than statements of historical facts, contained in this Current Report on Form 8-K, or furnished herewith, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as "may," "might," "will," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement, including, but not limited to: (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi)

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Presentation 99.2 Summary 99.3 Press Release dated June 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 4, 2024 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name: Vlad Vitoc Title: Chief Executive Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing